Treatment with obinutuzumab plus venetoclax reshapes the TRB repertoire of CLL patients
Saved in:
| Main Authors: | Paul J. Hengeveld, Joyce Schilperoord-Vermeulen, P. Martijn Kolijn, Julie M. N. Dubois, Peter E. Westerweel, Sabina Kersting, Arnon P. Kater, Mark-David Levin, Anton W. Langerak |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2025-01-01
|
| Series: | Blood Cancer Journal |
| Online Access: | https://doi.org/10.1038/s41408-025-01209-9 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Long-term follow-up of MRD-guided ibrutinib plus venetoclax in relapsed CLL: phase 2 VISION/HO141 trial
by: Carsten U. Niemann, et al.
Published: (2025-08-01) -
Venetoclax-Based Regimens in CLL: Immunoglobulin G Levels, Absolute Neutrophil Counts, and Infectious Complications
by: Wojciech Szlasa, et al.
Published: (2025-06-01) -
Venetoclax-based regimens in octogenarian patients with CLL: efficacy, safety, and comparison to BTKi in a multicenter cohort
by: Andrea Serafin, et al.
Published: (2025-07-01) -
scTCR-seq and HTS reveal a special novel TRBD2-TRBJ1 rearrangement in mammalian TRB CDR3 repertoire
by: Yingjie Wu, et al.
Published: (2025-04-01) -
Rethinking the feasibility and safety of venetoclax-obinutuzumab in chronic lymphocytic leukemia: non-traditional factors may play a role in clinical practice
by: Anna Maria Frustaci, et al.
Published: (2025-06-01)